Reviva Pharmaceuticals Holdings (RVPH) Cash & Equivalents (2018 - 2026)

Reviva Pharmaceuticals Holdings has reported Cash & Equivalents for 9 years, with the latest figure at $22.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 319.52% year-over-year to $22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (up 319.52% YoY) and the FY2025 annual result came in at $14.4 million, up 7.14% from the prior year.
• Cash & Equivalents rose to $22.2 million in Q1 2026 per RVPH's latest filing, from $14.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $23.4 million in Q1 2022 and troughed at $5.0 million in Q3 2023.
• A 5-year average of $14.0 million and a median of $13.2 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents plunged 78.56% in 2023, then jumped 319.52% in 2026.
• Over 5 years, Cash & Equivalents stood at $18.5 million in 2022, then gained by 26.18% to $23.4 million in 2023, then plunged by 42.33% to $13.5 million in 2024, then advanced by 7.14% to $14.4 million in 2025, then soared by 53.68% to $22.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $22.2 million, $14.4 million, and $13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.